David Wolf, M.D., specializes in Transplant Hepatology and - since 1996 – has been the Medical Director of the Liver Transplantation Program at Westchester Medical Center. Dr. Wolf has over thirty years of experience in gastroenterology and hepatology.

Dr. Wolf went on to serve on the faculties at the University of Cincinnati College of Medicine and the Mount Sinai School of Medicine, before joining the faculty at New York Medical College in 1996. Since then, he has received the Excellence in Housestaff Teaching Award six times. He has published more than 50 papers and 80 abstracts, focusing on topics including viral hepatitis, autoimmune hepatitis, portal hypertension, variceal bleeding, liver cancer and the economics of liver transplant.

In 1996, Dr. Wolf established the Liver Transplant Program at Westchester Medical Center, which was the first liver transplant program in the Hudson Valley. Over 1100 liver transplants have been performed at Westchester since the program’s founding. He sees patients with a broad array of liver diseases and has been recognized annually as a Castle Connolly New York Metro Area Top Doctor since 2006.

Dr. Wolf is very active in the transplant community. He lectures frequently to physician and patient organizations and served as the Medical Advisor for the Transplant Support Organization (TSO) for many years.

Areas of Expertise

• Treatment of alcohol-associated liver disease
• Treatment of metabolic dysfunction associated steatotic liver disease (MASLD)
• Treatment of hepatitis B and C
• Management of decompensated cirrhosis
• Post-liver transplant care

Education

• Fellowship: Gastroenterology and Hepatology, Albert Einstein College of Medicine
• Residency: Internal Medicine, Columbia Presbyterian Medical Center
• M.D., Columbia University College of Physicians and Surgeons
• B.S., Yale University
• Board-certified in Internal Medicine, Gastroenterology and Transplant Hepatology 

Honors and Awards

• Excellence in Housestaff Teaching, Westcheter Medical Center - 2001, 2013, 2016, 2017, 2018.
• Top Doctors, New York Metro Area, (Castle Connolly), 2006-present.
• Outstanding Professional Award, Transplant Support Organization - 2016.

Research

• Use of extended criteria donor organs in liver transplantation
• Optimizing use of HCV-positive allografts in liver transplantation
• Strategies to improve post-liver transplant outcomes
• Performance of liver transplant in patients with active alcohol use disorder

Publications

• Goetz A, Ryan N, Sauve-Ciencewicki A, et. al. "Assessing human carcinogenicity risk of agrochemicals without the rodent cancer bioassay." Frontiers in toxicology, 6(), (2024) 1394361. doi: 10.3389/ftox.2024.1394361
• Vermeire S, Sands BE, Peyrin-Biroulet L, et. al. "Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials." Journal of Crohn's & colitis, 18(11), (2024) 1780-1794. doi: 10.1093/ecco-jcc/jjae079
• Lewis JD, Daniel SG, Li H, et. al. "Surgery for Crohn's Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts." Cellular and molecular gastroenterology and hepatology, 18(3), (2024) 101357. doi: 10.1016/j.jcmgh.2024.05.005
• Cuvelier N, Avanasi R, Grunenwald M, et. al. "A Novel Approach to Integrate Human Biomonitoring Data with Model Predicted Dietary Exposures: A Crop Protection Chemical Case Study Using Lambda-Cyhalothrin." Journal of agricultural and food chemistry, 72(20), (2024) 11663-11671. doi: 10.1021/acs.jafc.3c07071
• Harris S, Feagan BG, Hanauer S, et. al. "Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease." Digestive diseases and sciences, 69(6), (2024) 2044-2054. doi: 10.1007/s10620-024-08391-z
• Dawkins M, Cheung N, Rozenblit G, et. al. "Intrahepatic Arterioportal Fistula With Subsequent Portal Hypertension After Percutaneous Liver Biopsy." ACG case reports journal, 11(3), (2024) e01287. doi: 10.14309/crj.0000000000001287
• Armuzzi A, Cross RK, Lichtenstein GR, et. al. "Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22(5), (2024) 1067-1076.e3. doi: 10.1016/j.cgh.2023.11.018

View All Publications

Professional Service

• American Liver Foundation, Greater New York Chapter, Member of Medical/Scientific Advisory Board
• Transplant Speakers International, Member of Advisory Council
• Empire Liver Foundation
• Transplant Support Organization, Medical Advisor

Memberships and Affiliations

• American College of Physicians, Fellow
• American College of Gastroenterology, Fellow
• American Gastroenterological Association, Fellow
• American Association for the Study of Liver Diseases, Fellow

Teaching Responsibilities

• Instruction of Westchester Medical Center Medicine Residents and Gastroenterology fellows